Bavarian Nordic Welcomes Gerard van Odijk as New Chairman of the Board

KVISTGAARD, Denmark, April 24, 2014 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today, that following the ordinary general meeting, the board has elected Gerard van Odijk, M.D. as new chairman of the board of Bavarian Nordic. He succeeds Asger Aamund who has served as chairman since 1994. Furthermore Anders Gersel Pedersen, M.D. has been elected deputy chairman of the board.

Dr. van Odijk has served as board member in Bavarian Nordic since 2008. He is an independent advisor for the pharmaceutical industry in which he has long-time experience from various executive positions. He retired as president and CEO of Teva Pharmaceuticals Europe B.V. in 2012 and has previously held various senior positions in GlaxoSmithKline (GSK).

Dr. van Odijk is also chairman of the board of Merus Biopharmaceuticals B.V. and member of the board of UDG Healthcare plc. He is a Dutch national, born in 1957.

Anders Gersel Pedersen, M.D. and deputy chairman has served on the board since 2010. Dr. Pedersen is executive vice president of research and development at H. Lundbeck A/S. He is deputy chairman of the board of Genmab A/S and a member of the board of directors of ALK-Abelló A/S. Dr. Pedersen is a Danish national, born in 1951.

Anders Hedegaard, President & CEO of Bavarian Nordic said: “After having served on the board for more than five years, we are happy to welcome Gerard as new chairman of the board. His inside knowledge from our company combined with his extensive executive background within publicly traded companies in the international pharmaceutical industry will contribute to our continued progress in the coming years.”

Anders Hedegaard, President & CEO.

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47 43
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. The vaccine is approved in Canada under the trade name IMVAMUNE and in the European Union under the trade name IMVANEX®.

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visit

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Company Announcement no. 7 / 2014